enGene changes name to enGene Therapeutics as it nears commercialization

enGene Holdings Inc. (NASDAQ: ENGN) announced it will change its corporate name to enGene Therapeutics Inc. effective April 8, 2026. The clinical-stage biotechnology company said the name change reflects its transition toward becoming a commercial organization ahead of potential approval of its lead drug candidate detalimogene voraplasmid in 2027.

The company plans to submit a Biologics License Application for detalimogene in the second half of 2026. The drug candidate is currently being evaluated in the ongoing LEGEND Phase 2 trial for high-risk non-muscle invasive bladder cancer, including a pivotal cohort studying BCG-unresponsive patients with carcinoma in situ.

"We're entering an important next phase for enGene as we prepare for potential approval of detalimogene in 2027," said Ron Cooper, President and Chief Executive Officer. "Our new name reflects our progress — and the opportunity to bring detalimogene to patients and the practices that care for them, where more options are still needed."

The company's common shares will continue trading on the Nasdaq Capital Market under the symbol "ENGN," while warrants will maintain the symbol "ENGNW." The name change will not affect security holder rights and requires no action from shareholders.

New CUSIP and ISIN numbers will be assigned effective with the name change. The new CUSIP number for common shares will be 29286X101 with ISIN CA29286X1015, while warrants will have CUSIP 29286X119 and ISIN CA29286X1197.

Detalimogene has received Regenerative Medicine Advanced Therapy and Fast Track designations from the FDA. The drug candidate was developed using the company's proprietary Dually Derivatized Oligochitosan platform for non-viral gene therapy delivery.

You May Also Be Interested In

• ONAR Holding regains SEC reporting status, posts revenue gains
• Securitize adds two banking veterans to its board of directors
• CoStar Group names Robin Rossmann as CFO, effective July 2026